Sartorius Stedim Biotech S.A.
SRTOY News Today: Stay Updated with the Latest Sartorius Stedim Biotech S.A. News in Real Time
Find SRTOY news now at Meyka AI. Stay informed with the latest Sartorius Stedim Biotech S.A. stocks updates, including price news, market analysis, and expert insights.
ENDV Stock Surges 9900% on May 7, 2026 – Endonovo Therapeutics Gains
ENDV stock jumps 9900% to $0.0001 on May 7, 2026. Endonovo Therapeutics gains momentum on PNK exchange with 500K volume.
MDG1.F stock surges 59.5% on May 7 as Medigene AG rallies on XETRA
MDG1.F stock jumps 59.5% to €0.0386 on May 7, 2026. Medigene AG shows strong intraday gains on XETRA exchange amid liquidation phase.
NSRX Insider Trade: Rubin Eyal CFO Share Options Filing May 2026
Nasus Pharma CFO Rubin Eyal files initial ownership of 40,549 share options worth $306,550. Form 3 filing reveals executive compensation structure.
IDIA.SW stock surges 6.9% on May 7, 2026 amid biotech momentum
IDIA.SW stock jumps 6.9% to CHF 3.978 on SIX exchange. Idorsia Ltd biotech gains momentum with strong volume activity.
0399.HK Surges 32.7% on May 7 as Starcoin Group Gains Momentum
Starcoin Group Limited (0399.HK) jumps 32.7% to HK$0.073 on May 7, 2026. HKSE trading shows strong volume surge and technical recovery signals.
MMTX.SW Surges 26.9% on May 7 as MindMaze Therapeutics Gains
MMTX.SW stock jumps 26.9% to CHF0.42 on SIX. MindMaze Therapeutics gains momentum in biotech sector.
4883.T Stock Drops 20% as Modalis Therapeutics Falls on JPX
Modalis Therapeutics (4883.T) plunges 20% on JPX. Stock hits ¥64, down from ¥80. CRISPR gene therapy firm faces headwinds.
Zealand Pharma Jumps 12% After Q1 Revenue Beat and DKK 1.3B Buyback
Zealand Pharma shares surged around 12% after the company reported better than expected Q1 revenue and announced a large share buyback program worth DKK 1.3 billion. The strong performance reflected investor confidence in the company’s growth outlook and its expanding pipeline in metabolic and rare disease treatments. The rally in Zealand Pharma also attracted attention…
WAT: UBS Maintains Neutral Rating, Raises Price Target to $375
UBS maintains Neutral rating on Waters Corporation (WAT), raising price target to $375 from $330 on May 6, 2026.